Antifibrotic effects of tocotrienols on human Tenon's fibroblasts by Tappeiner, Christoph et al.
GLAUCOMA
Antifibrotic effects of tocotrienols on human
Tenon’s fibroblasts
Christoph Tappeiner & Alexander Meyenberg & David Goldblum & Daniel Mojon &
Jean-Marc Zingg & Kalanithi Nesaretnam & Monika Kilchenmann & Beatrice E. Frueh
Received: 27 December 2008 /Revised: 27 May 2009 /Accepted: 27 July 2009 /Published online: 14 August 2009
# Springer-Verlag 2009
Abstract
Purpose To compare the antifibrotic effect of vitamin E
isoforms α-, γ-, and δ-tocotrienol on human Tenon’s
fibroblasts (hTf) to the antimetabolite mitomycin C.
Methods Antifibrotic effects of α- (40, 60, 80, 100, and
120 μM), γ- (10, 20, 30, and 40 μM) and δ-tocotrienol (10,
20, 30, and 40 μM) on hTf cultures were evaluated by
performing proliferation, migration and collagen synthesis
assays. Whereas for vitamin E the exposure time was set to
7 days to mimic subconjunctival application, cultures were
exposed only 5 min to mitomycin C 100 μg/ml to mimic
intraoperative administration. Cell morphology (phase
contrast microscopy) as an assessment for cytotoxicity and
cell density by measuring DNA content in a fluorometric
assay to determine proliferation inhibition was performed
on day 0, 4, and 7. Migration ability and collagen synthesis
of fibroblasts were measured.
Results All tested tocotrienol isoforms were able to signifi-
cantly inhibit hTf proliferation in a dose-dependent manner
(maximal inhibitory effect without relevant morphological
changes at day 4 for α-tocotrienol 80 μM with 36.7% and at
day 7 for α-tocotrienol 80 μM with 42.6% compared to
control). Degenerative cell changes were observed in cultures
with concentrations above 80 μM for α- and above 30 μM for
γ- and δ-tocotrienol. The highest collagen synthesis inhibition
has been found with 80 µM α-tocotrienol (62.4%) and no
significant inhibition for mitomycin C (2.5%). Migration
ability was significantly reduced in cultures exposed to 80 µM
α- and 30 µM γ-tocotrienol (inhibition of 82.2% and 79.5%,
respectively, compared to control) and also after mitomycin C
treatment (60.0%). Complete growth inhibition without
significant degenerative cell changes could only be achieved
with mitomycin C.
Conclusion In vitro, all tested tocotrienol isoforms were
able to inhibit proliferation, migration and collagen
synthesis of human Tenon’s fibroblasts and therefore
may have the potential as an anti-scarring agent in
filtrating glaucoma surgery.
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Introduction
Postoperative fibrosis of the filtering bleb or of the
surgical fistula is a known cause of failure in glaucoma
surgery [1, 2]. Tenon’s fibroblasts are assumed to be the
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main component of scar tissue in glaucoma surgery [2].
Antimetabolites as mitomycin C and 5-fluorouracil are
currently used as anti-scarring drugs in glaucoma surgery,
especially in eyes with an elevated risk of bleb scarring,
but may hold the risk of postoperative complications, e.g.,
ocular hypotonia (bleb leakage), conjunctival necrosis of
the filtering bleb, or endophthalmitis because of cytotoxic
side effects [3–10]. Although recent studies have shown
encouraging results for mitomycin C with a relatively low
complication rate [11], alternative agents may still be
useful. In cancer research, the antiproliferative and
apoptotic effects of different vitamin E forms have been
shown. Vitamin E acts as an antioxidant with neuro-
protective, antithrombotic, anti-inflammatory and antineo-
plastic effects through its involvement in the intracellular
signaling pathway [12–16]. Vitamin E is the generic name
for two subclasses (tocopherols and tocotrienols), which
itself consist of different isoforms. Vitamin E inhibits the
proliferation of human Tenon’s capsule fibroblasts in vitro
[17]. In a previous in vitro study of our group, only α-
tocotrienol showed antiproliferative effects without signif-
icant toxicity on human Tenon’s fibroblasts compared to
α-tocopherol, α-tocopheryl-acetate, and α-tocopheryl-
succinate. A 50% growth inhibition could be achieved
using 50 μM of α-tocotrienol [18]. Higher (and therefore
eventually more effective) concentrations have not been
tested. Based on prior studies [19–21] γ- und δ-isoforms
of tocotrienol may even have a better antiproliferative
effect than α-tocotrienol. Therefore, the aim of this study
was to evaluate the tocotrienol isoform with the highest
antifibrotic effect compared to mitomycin C in vitro. For
this purpose, we performed a proliferation, cell migration,
and collagen deposition assay. Degenerative cell changes
produced by vitamin E isoforms and mitomycin C were
assessed by phase contrast microscopy.
Materials and methods
Reagents
RRR-α-, RRR-γ-, and RRR-δ-tocotrienol (α-T3, γ-T3, δ-T3)
were a kind gift from the Malaysian Palm Oil Board (Kuala
Lumpur, Malaysia). Vitamin E forms were dissolved in
ethanol absolute and then stored light-protected at 4°C.
Mitomycin C was purchased from Kyowa (distributed by
Roche Pharma, Reinach, Switzerland) and dissolved freshly
in phosphate-buffered saline (PBS) before use.
Cell cultures
Explants of human Tenon’s capsule were obtained from
seven patients at the time of cataract surgery. All patients
gave their informed consent before inclusion in the
study, which was approved by the local ethics committee
and conformed to the provisions of the Declaration of
Helsinki. The seven different human Tenon fibroblast
cultures were thawed and placed in 25-cm2 tissue culture
flasks containing Dulbecco`s minimal essential medium
(DMEM) supplemented with L-glutamine (584 mg/l),
sodium pyruvate (100 mg/l), glucose (1,000 mg/l),
penicillin (60 U/ml), streptomycin (60 μg/ml) and 10%
fetal calf serum (FCS). None of the seven donors, aged
68–93 years, had antiglaucomatous, antimetabolite, or any
other ocular treatment, or ocular surgery before the
corneo-scleral cataract surgery, when Tenon specimens
were taken. Cultures were maintained in a humidified 5%
CO2 incubator at 37ºC. Confluent cultures were trypsi-
nized, centrifuged, and repassaged. The above medium
was changed twice per week. As quantified by trypan blue
dye exclusion method, viability was always more than
95%. For the assays, third- to fifth-passage cells were
used. All assays were performed on all cell lines in
triplicate.
Cell proliferation assay
Fibroblasts were seeded at a density of 1,500 cells/well
in 96-well tissue culture plates (black/clear-bottom,
Corning Life Sciences), with each well containing
200 μl of culture medium. Fibroblasts were washed with
PBS 24 h after plating and incubated for another 48 h
with DMEM containing 0.2% FCS to induce growth arrest
[2]. At day 0, cells were rinsed with PBS and cell growth
was restimulated with adding fresh DMEM/10% FCS.
Tocotrienols were immediately diluted to the indicated
concentrations (40, 60, 80, 100, and 120 µM α-tocotrienol,
10, 20, 30, and 40 µM γ-tocotrienol and 10, 20, 30, and 40
µM δ-tocotrienol) in above media. Cells treated with an
equivalent amount of ethanol absolute (0.8 μl/well) were
included as control.
Mitomycin C was dissolved in PBS to concentrations of
10, 100, and 400 µg/ml. Growth-arrested cells were
exposed for exactly 5 min to 100 µl/well mitomycin C
solution. Fibroblasts were then gently washed with PBS
alone and fed with 200 µl/well DMEM/10% FCS again.
Multiple rinsing with PBS was not performed since a
decrease in cell density was observed in preliminary
studies. PBS-treated cultures served as control. The plates
were then incubated for 7 days at 37ºC in 5% CO2 in a
humidified air atmosphere. No media was changed during
this time.
Cell morphology was studied at day 0, 1, 4, and 7 using
phase contrast light microscopy (Leica DMIRB research
microscope, Leica Microsystems, Wetzlar, Germany). Pho-
tomicrographs were obtained with a color camera (Kappa
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CF15 MC, Kappa Messtechnik, Gleichen, Germany)
connected to a video printer (Sony UP-5200MDP, Sony,
Schlieren, Switzerland). Images were evaluated by a
masked investigator.
As recently described in detail [18], cell density was
finally determined with a fluorometric assay (CyQUANT
Cell Proliferation Assay Kit, Molecular Probes, distributed
by JURO Supply, Lucerne, Switzerland) measuring DNA
content of each well at days 0, 4, and 7.
Collagen synthesis assay
Collagen content was analyzed with a Sircol Soluble
Collagen Assay (Biodye Science, Cologne, Germany) for
cell cultures 4 days after exposure to α-tocotrienol, δ-
tocotrienol, γ-tocotrienol (control: exposure to ethanol abs.
0.8 µl) and mitomycin C (100 µg/ml, exposure time 5 min;
control: exposure to PBS). Sirius red binds specifically to
soluble collagen and can be quantified with a colorimeter.
Cell migration assay
Effect of tocotrienol and mitomycin C on migration ability of
Tenon’s fibroblasts was tested with a CytoSelect 96-well Cell
Migration and Invasion Assay (Cell Biolabs, Inc., distributed
by JuroScience GmbH, Lucerne, Switzerland) 2 days after
exposure to tocotrienols or mitomycin C. The migration assay
kit contains polycarbonate membrane inserts (8-µm pore size)
in a 96-well plate. The membrane is a barrier discriminating
cells with migration towards chemoattractants in the medium
above the membrane. These cells were then dissociated from
the membrane, and then a lysis and DNA-extraction is
performed and cell count determined with a cytofluorometer
as described above.
Fig. 1 Effects of incubation with different tocotrienols in variable
concentrations for 7 days or exposure to mitomycin C for 5 min on
human Tenon’s fibroblast proliferation. A fluorometric assay deter-
mined proliferation by DNA content quantification at days 0, 4, and 7.
Means of cell numbers/well of seven different cell cultures in triplicate
are presented. Significantly reduced values, compared to control, are
marked with one (p<0.05) or two (p < 0.01) stars
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Statistical analysis
The relationship between the fluorescence signal and the
number of cells/well was very strongly linear (Pearson
correlation coefficient r=0.99). Results of the proliferation
assay are therefore presented as the mean number of cells/well.
Inhibition of proliferation, migration, and collagen synthesis
were also expressed as percentages of inhibition compared to
control. Differences between control and compound values
were analyzed by Friedman's test followed by the non-
parametric Dunnett's test based on rank sum as post-hoc
analysis. Wilcoxon rank-sum test was used when appropriate.
The criterion for statistical significance was p<0.05.
Results
Cell proliferation and morphology
Figure 1 and Table 1 summarize the results of the
proliferation assay. All tested tocotrienol forms were able to
significantly inhibit fibroblast proliferation at days 4 and 7,
and effects occurred in a dose-dependent manner. Strong
antiproliferative effects but no relevant degenerative cell
changes were observed in cultures treated with 80 µM α-T3,
30 µM γ-T3, and 30 µM δ-T3. At these concentrations, cell
densities were statistically comparable at day 4 (α-T3 3,709±
1,394 (mean ± SD) cells/well, γ-T3 3,723±2,160 cells/well,
δ-T3 3,820±2,063 cells/well; p=0.87) and day 7 (α-T3
3,714±1,524 cells/well, γ-T3 4,147±1,781 cells/well, δ-T3
4,281±2,186 cells/well; p=0.57) between all three tocotrie-
nol forms. There was, however, considerable variation of the
antiproliferative effect of all three tocotrienol forms between
the seven different cell lines.
At higher concentrations, all tocotrienol forms led to
nuclear and cytoplasmic condensation (Fig. 2).
Five-minute exposure to 100 µg/ml mitomycin C resulted
in complete growth inhibition without affecting cell morphol-
ogy (day 0, control 2,208±720 cells/well; day 7, 100 µg/ml
mitomycin C 2,187±647 cells/well; Wilcoxon test: p=0.81).
Viability of cultures treated with 400 µg/ml mitomycin C
was severely compromised (Fig. 2). Since α-tocotrienol 80
µM, δ-tocotrienol 30 µM and γ-tocotrienol 30 µM were the
tocotrienol concentrations with the best antiproliferative
effect without relevant degenerative cell changes, only these
concentrations were used in the further assays.
Collagen production
Comparing collagen content of different cell cultures
(Fig. 3, Table 1) after exposure to tocotrienol and
mitomycin C revealed significant inhibition of collagen
synthesis for α-tocotrienol 80 µM, γ-tocotrienol 30 µM and
δ-tocotrienol 30 µM (Friedman ANOVA, p=0.0002;
Dunnmatt post-hoc test p<0.05, each) with the highest
inhibition for 80 µM α-tocotrienol, whereas mitomycin C
did not inhibit collagen synthesis (Wilcoxon one-tailed test;
p=0.23). Collagen content in the mitomycin C control
(PBS) did not differ from that of the tocotrienol control
(ethanol) (Wilcoxon two-tailed test; p=0.47).
Cell migration ability
Migration ability (Fig. 4, Table 1) was significantly
reduced in the proliferation assay exposed to α-
tocotrienol 80 µM and γ-tocotrienol 30 µM compared to
the ethanol control (Dunnett post-hoc test, p<0.01, each;
Friedman ANOVA, p<0.0001) and also for the mitomycin
C assay compared to the PBS control (Wilcoxon one-
tailed test; p=0.02). No significant inhibition of cell
migration could be shown for α-tocotrienol 40 and 60
µM and δ-tocotrienol 30 µM (p>0.05, each). There was
no significant difference between the tocotrienol (ethanol)
and the mitomycin C control group (PBS) (Wilcoxon two-
tailed test; p=0.58).
Table 1 Effects of incubation with different tocotrienols in variable
concentrations for 7 days or exposure to mitomycin C for 5 min on
human Tenon’s fibroblast migration (M), proliferation (P), and
collagen synthesis (C) expressed in percentages of inhibition com-
pared to control group at specific time points (days 2, 4, and 7)
Day 2 Day 4 Day 7
% M % P % C % P
α-tocotrienol
40 μg/ml 20.7 13.2 −0.7 13.6
60 μg/ml 57.7 23.5 33.0 16.7
80 μg/ml 82.2 36.7 62.4 42.6
100 μg/ml n.a. 48.1 n.a. 44.1
120 μg/ml n.a 63.0 n.a. 71.0
γ-tocotrienol
10 μg/ml n.a. 6.5 n.a. 6.0
20 μg/ml n.a. 10.1 n.a. 10.3
30 μg/ml 79.5 36.5 56.5 35.9
40 μg/ml n.a. 33.3 n.a. 42.5
δ-tocotrienol
10 μg/ml n.a. 9.2 n.a. 5.6
20 μg/ml n.a. 22.8 n.a. 12.3
30 μg/ml 57.1 34.8 60.4 33.8
40 μg/ml n.a. 65.1 n.a. 62.0
mitomycin C
10 μg/ml n.a. 35.8 n.a. 31.2
100 μg/ml 25.7 55.8 2.5 60.0
400 μg/ml n.a. 71.0 n.a. 77.6
Significant results (p<0.05) are marked in bold
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Discussion
The outcome of filtrating glaucoma surgery depends on the
amount of wound healing and scarring. In a review of Lama et
al., pathways involved in wound healing after glaucoma
surgery are described, including vascular leakage, coagulation,
cellular migration, granulation tissue, and scar formation [22].
Antimetabolites such as mitomycin C and 5-fluorouracil are
used in filtrating glaucoma surgery to reduce bleb scarring in
patients at risk for postoperative bleb failure [3–5]. Due to
their cytotoxic effectiveness, hypotony and endophthalmitis
may occur [10, 23]. The dose-dependent effect of
mitomycin C on apoptosis was shown by Crowton et al.
[24]. Although experience with mitomycin C revealed an
Fig. 2 Phase contrast
photomicrographs of human
Tenon’s fibroblasts on day 7
of the proliferation assay. a
control; b 400 μg/ml mitomycin
C; c 80 μM α-tocotrienol; d
120 μM α-tocotrienol; e 30 μM
γ-tocotrienol; f 40 μM γ-
tocotrienol; g 30 μM
δ-tocotrienol; h 40 μM δ-
tocotrienol. (representative
photographs were obtained from
fibroblasts in the center of the
well. Magnification: all x 50)
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acceptable safety profile [25, 26], alternative antiprolifer-
ative agents with less cytotoxic and cell degenerative
effects compared to mitomycin C would still be needed.
In prior studies, vitamin E isoforms have revealed an
antifibrotic potential [17–19, 21]. Based on these findings,
we evaluated the effects of different tocotrienol isoforms
and concentrations on human Tenon’s fibroblasts regarding
inhibition of proliferation, migration, and collagen synthe-
sis, revealing a significant antifibrotic effect for all tested
isoforms.
This study focused on inhibition of proliferation,
migration, and collagen synthesis, whereas other possible
factors involved in wound-healing are not fully covered.
Prior studies have also evaluated the effects of vitamin E
isoforms on angiogenesis, apoptosis, and cytotoxic effects
[27–30]. In a previous study of our group, the application
of tocotrienol at a concentration of 100 µM did not lead to
an increase of glucose 6-phosphate dehydrogenase release
as a measure for dying cells [18]. However, synthetic forms
of vitamin E such as α-tocopheryl-succinate led to
significant increased G6PD levels. Considering α-
tocotrienol, degenerative cell changes were only observed
after repeated application of 50 µM. In the present study, 80
µM α-tocotrienol showed a significant anti-proliferative
effect without relevant morphologic changes as well.
Exposure times of hTf to tocotrienols (7 days) and
mitomycin C (5 min) have been chosen on purpose to be
different in our study. During glaucoma filtration surgery,
the application time of mitomycin C is commonly limited to
a few minutes. Such a short-time application is unlikely to
be suitable for tocotrienols. To the best of our knowledge, it
is difficult to formulate a type of tocotrienol capable of
realizing a sufficiently high and stable concentration such
as needed in an intraoperative application of a few minutes
as cellular uptake of tocotrienols is rather a matter of hours
than minutes [31]. We therefore used a long-term applica-
tion approach, which clinically could be obtained for
example with a subconjunctival injection of the compound.
Our results should encourage for further dose-finding and
toxicity studies, as in-vitro concentrations are not directly
portable to in-vivo use. As mitomycin C at a concentration
of 100 μg/ml revealed the best effect without significantly
toxicity, we decided to chose only this concentration for
migration and collagen synthesis assays.
Whereas in our study mitomycin C as well as α-tocotrienol
80 µM and γ-tocotrienol 30 µM significantly reduced cell
migration of hTf, the antiproliferative effect of mitomycin C
was higher compared to tocotrienol. On the other hand,
mitomycin C (100 µg/ml, 5 min exposure time) did not reveal
significant inhibition of collagen production in contrast to
tocotrienol (α-tocotrienol 80 µM, γ-tocotrienol 30 µM and
δ-tocotrienol 30 µM). Because of this advantage, tocotrienol
may have a certain potential as an agent for filtrating
glaucoma surgery as collagen synthesis is an important factor
for bleb and surgical fistula scarring in glaucoma filtrating
surgery [32, 33]. The results of our study are encouraging for
further research as tocotrienols may offer the potential as an
alternative agent to currently used anti-scarring drugs as
mitomycin C or 5-fluorouracil. As tocotrienol isoforms are
lipid-soluble agents, subconjunctival drug application could
be difficult and an appropriate carrier substance may have to
be used.
In vitro, all tested tocotrienol isoforms have revealed
good antiproliferative effectiveness on human Tenon’s
fibroblasts. Further in vitro and in vivo studies will be
necessary to evaluate the safety and the potential role of
tocotrienol as a mean to prevent bleb failure in filtrating
glaucoma surgery.
Fig. 4 Cell migration assay (8 µm pore size; migration time 48 h)
for different tocotrienol isoforms/concentrations and mitomycin C.
(* p<0.05)
Fig. 3 Collagen content in cell cultures 4 days after exposure to
tocotrienol and mitomycin C showing significant collagen synthesis
inhibition with α-totoctrienol 80 µM, γ-tocotrienol 30 µM, and
δ-tocotrienol 30 µM (* p<0.05, each) and no significant inhibition for
mitomycin C 100 μM
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